Open AccessTreatment with an anti‐CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis
Author(s) -
PELEGRÍ C.,
MORANTE M. P.,
CASTELLOTE C.,
FRANCH A.,
CASTELL M.
Publication year - 1996
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1996.d01-624.x
Subject(s) - arthritis , medicine , immunology , adjuvant , cd8 , monoclonal antibody , inflammatory arthritis , disease , antibody , antigen
Some experimental arthritic diseases can be prevented by treatment with anti‐CD4 MoAbs. Trials with ongoing disease have not been successful so far. The aim of this study was to ascertain whether W3/25 could reverse adjuvant arthritis (AA), when beginning treatment on day 14, i.e. when the disease was established. Moreover, one group of animals treated with the anti‐CD4 MoAb received OX8 MoAb at the same time, thus depleting CD8 + cells from circulation. During treatment with W3/25, a strong amelioration of inflammatory signals was observed, as assessed by means of paw volume increase and arthritic score. However, when treatment stopped, a rebound to arthritis signals occurred. The parallel depletion of CD8 + cells did not modify these effects, thus the combined treatment W3/25+OX8 gave the same amelioration as treatment with W3/25 alone. These findings indicate that CD4 + cells play an important role in perpetuating rat AA. Moreover, CD8 + cells do not seem to have a regulatory role in the CD4 + cells responsible for the inflammatory response.